Diabetic Macular News Today : Breaking News, Live Updates & Top Stories | Vimarsana

High dose aflibercept reduced treatment burden in patients with diabetic macular edema

1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across all intervention groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Diabetic macular oedema (DMO) leads to vision loss in 5% of patients with diabetes. Anti-vascular endothelial growth factor (anti-VEGF) medications, such as

Rating levelBevacizumab firstDiabetic macularBetween jun

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Completed enrollment in Phase 2b RELIEF trial of Licaminlimab , anti-TNF alpha eye drops in Dry Eye Disease ; topline results expected in Q2 2024Second Phase 3 trial of OCS-01 eye drops in Diabetic.

United statesEastern virginia medical schoolFrance generalSylvia cheungJoanne changElizabeth yeuCorey davisRamin tadayoniArshadm khananiMacula societyEuropean society of retina specialistsRetina research foundationRetina societySteering committeeOculis holding ag nasdaqAmerican academy of ophthalmology achievement award

Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8

Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLou gehrigJayakrishna ambatiPaul ashtonBeverly jedynakUniversity of kentuckyClinical trialIntravitreal injectionNucleoside reverse transcriptase inhibitorDiabetic macularMichelle abou jaoudeGeographic atrophyDry age related macularInflammasome therapeuticsMultiple sclerosisBevlyn consulting

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMacau generalHong kongChristina tartagliaAmy phillipsJay dukerGreen room communicationsEyepoint pharmaceuticals nasdaqExchange commissionEyepoint pharmaceuticalsEquinox sciencesEyepoint pharmaceuticals incDrug administrationDiabetic macularPoint pharmaceuticalsChief executive officer

Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema

Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesAshkan abbeyDavid callananMohamed geneadTexas retina associatesAnnounces first patient enrolledTrial evaluatingDiabetic macularChief medical officrSenior viceAviceda therapeutics